The NanoGene Team
Sharif Ali, M.D.
Founder & CEO
Dr. Ali is an American board-certified anatomical and clinical pathologist and hematopathologists. He has over 15 years’ experience providing exceptional care delivering accurate and precise diagnosis in the field of blood and bone marrow disorders.
Sharif A. Ali, MD
Founder & CEO
Dr. Ali is an American board-certified anatomical and clinical pathologist and hematopathologists. He has over 15 years’ experience providing exceptional care delivering accurate and precise diagnosis in the field of blood and bone marrow disorders. Dr. Ali is a renowned expert in the field of renal pathology, with a primary focus on segmental glomerulosclerosis. He has also multiple publications on cellular rejection of liver transplants and has a keen academic interest in transplant immunology and T-cell lymphomas.Throughout his career, he has performed over 2,000 therapeutic apheresis procedures.
Dr. Ali has authored more than 20 publications as abstract or peer reviewed articles and is an active educator at the University of South Florida College of Medicine, where he served as an assistant professor of Pathology and Medicine. He is a Fellow and Member of the College of American Pathology, and a Fellow of the American Society of Clinical Pathology. Dr. Ali has multiple awards including fellow of the year by the College of American Pathologist in 2011, and best pathologist in Pennsylvania. He is also a member of the Pennsylvania Society of Pathology and Association for Molecular Pathology.
Dr. Ali is inspired by the innovative and rapidly growing healthcare in the UAE. He was impressed by the country's unwavering commitment to offering cutting-edge medical facilities and services to its citizens and residents.
This admiration led him to establish Nanogene, a venture aimed at addressing the need for specimen send-out to the United States and Europe for oncology and renal pathology testing. The laboratory is fully committed to delivering dependable results that directly contribute to enhancing patient outcomes.
Education and Training:
- 1997-2005: Medical School and Internship - Ain Shams University, Cairo Egypt
- 2007-2011: Anatomical and Clinical Pathology Residency - Henry Ford Health System, Detroit, Michigan
- 2011-2012: Transplant Immunology and Renal Pathology Fellowship - University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
- 2012-2013: Hematology/Hematopathology Fellowship Training - New York Langone Medical Center, New York, New York
- 2018-2020: MBA in Healthcare Informatics - Southeastern Oklahoma State University (SE), with supplemental classes at the Wharton School of Business, University of Pennsylvania
Certifications:
- American Board of Pathology (Anatomical and Clinical Pathology), initial certification in 2011, renewed 2021 for 10 years.
- American Board of Pathology (Hematology/Hematopathology), initial certification in 2013, renewed 2021 for 10 years.
- Laboratory Medical Director Certification from the University of Iowa, earned in 2018.
- American Society of Clinical Pathology (ASCP)certification of Apheresis, renewed in 2023.
Work Experience:
- 2013-2018: Chief of Renal Pathology, Interim Blood Bank Director, Hematopathologist at Lehigh Valley Health System in Allentown, Pennsylvania.
- 2018-2022: Chief of Pathology and Laboratories Medical Director at Conemaugh Health System labs, overseeing Memorial, Meyersdale, Nanson, and Minors Hospitals in Johnstown, Pennsylvania.
- 2023-present: Medical Director at Inova Reference Laboratory, serving as a Hematopathologist and Apheresis Physician.
Mohammed Zuhair Ahmed
Chief Operating Officer x OPTUM | UnitedHealthGroup
Mohammed Zuhair Ahmed
Chief Operating Officer x OPTUM | UnitedHealthGroup
Andrea Zanon, MBA
Head Of Business Development World Bank, Washington DC
With 25 years of entrepreneurship, operations, sustainability and technology leadership experience, Andrea brings a hands-on practical approach to partnering with Investors, Corporate Boards, Management Teams, Customers and Minister of Finance to create accelerated returns, resilient investment, long-term growth, and market leadership.
Andrea Zanon, MBA
Head Of Business Development
World Bank, Washington DC
Najette Ezzarqui
Director of Operations
NanoGene is pleased to welcome Najette to our team. With over 20 years of experience in educational and retail expertise with the renowned luxury French brand Chanel, Najette brings a wealth of knowledge and skills to her role.
Najette Ezzarqui
Director of Operations
Salem Nasser Salmeen
Executive Director of the Private Office of His Highness Sheikh Hamdan bin Mohammed Al Nahyan. Outreach & Partnership
المدير التنفيذي للمكتب الخاص لسمو الشيخ حمدان بن محمد آل نهيان
Salem has established robust connections with the UAE government and health authorities. He will be leading Nanogene's engagement with these entities.
Salem Nasser Salmeen
Executive Director of the Private Office of
His Highness Sheikh Hamdan bin Mohammed Al Nahyan
Outreach & Partnership
المدير التنفيذي للمكتب الخاص لسمو الشيخ حمدان بن محمد آل نهيان
Salem has established robust connections with the UAE government and health authorities. He will be leading Nanogene's engagement with these entities.
Our Top Pathologists & Scientists
Rodney Wiltshire, Ph.D
Cytogenetic and Molecular Lab Co-Director
Dr. Rodney Wiltshire has worked in the field of Human Genetics for over 30 years,making significant contributions to the academic research and commercial clinical diagnostic sectors, focusing on cancer...
Rodney Wiltshire, PhD
Cytogenetic and Molecular Lab Co-Director
Dr. Rodney Wiltshire has worked in the field of Human Genetics for over 30 years,making significant contributions to the academic research and commercial clinical diagnostic sectors, focusing on cancer cytogenetics and molecular genetics. He earned his Ph.D. from The University of Michigan, Department of Human Genetics, Ann Arbor, Michiganin 1997. In conjunction with a fellowship from the National Human Genome Research Institute at the National Institutes of Health,Bethesda, Maryland, he published several papers investigating the progressive stages of human cutaneous melanoma. He continued his postdoctoral research training at Duke University Medical Center, Pathology Departmentin Durham, North Carolina, where he authored numerous scientific articles onthe cytogenetic and molecular genetic characterizations of neurological tumors, including glioblastoma, astrocytoma, and medulloblastoma.While at Duke, he completed the Clinical Cytogenetics Fellowship in their Integrated Genetic Training Program in 2002 and has since heldthe American Board of Medical Genetics and Genomics certification in Clinical Cytogeneticsand Genomics.
Over the last 17 years, Dr. Wiltshire has worked as the Cytogenetics Laboratory Directorin various commercial diagnostic reference laboratories and holds New York and New Jersey StateLicensures as a Cytogenetics Laboratory Director. Heestablished the Cytogenetics Department and held the Scientific Director position at the medium-sized reference laboratory NHL Lab Medicine in Allentown, Pennsylvania. Throughout his extensive and diverse career, Dr. Wiltshirehas beenhighly proficient in developing and directing clinical diagnostic laboratories in utilizing cytogenetics, molecular genetics, and genomicdiagnostic technologies for analyzing cancer patients’ specimens.
Dr. Wiltshire’sinterests include fostering high-level genetic educational initiatives, developing novel molecular diagnostic methodologies for early cancer detection, and investigating the impact of genomic sequences on the origins and progression of genetic disorders and neoplasms.
Ather Naseemuddin, M.D.
Clinical Head, Surgical Pathology & Cytopathology
Dr. Naseemuddin completed his Medical School at Aligarh Muslim University in India in 2002. Dr. Naseemuddin then decided to pursue a career in pathology and completed an AP residency in Saint Luke’s Roosevelt Health Center (Now part...
Dr. Naseemuddin
(Head of Anatomical Pathology, surgical pathology and cytopathology)
Dr. Naseemuddin completed his medical school education at Aligarh Muslim University in India in 2002. Afterward, he decided to specialize in pathology and completed an AP residency at Saint Luke's Roosevelt Health Center (now part of the Mount Sinai Health Care System) in New York, New York 2005-2008. He further pursued his training with a surgical pathology fellowship at Washington University in St. Louis, Missouri in2008- 2009, and a Cytopathology fellowship at Henry Ford Hospital in Detroit, Michigan in 2009-2010.
Currently, Dr. Naseemuddin serves as a pathologist at the Saint John Regional Hospital in New Brunswick, Canada since 2010. In 2019, he was appointed as the Clinical Head of the Department of Laboratory Medicine, a position he currently holds. Additionally, he holds academic appointments as an Assistant Professor of Pathology at Dalhousie University in Nova Scotia and Memorial University of Newfoundland.
In addition to his day-to-day diagnostic work, Dr. Naseemuddin has actively participated in various Selection Committees and the Medical School Admission Committee. He is also an integral part of the Forensic Pathology Services for the province of New Brunswick, where he has conducted numerous medicolegal examinations and provided court testimonies in cases of national prominence.
Dr. Naseemuddin strongly believes in the importance of checklists, standardized practices, and consistent incremental improvement to deliver high-quality laboratory services. His role as the Clinical Head has given him valuable insights into achieving and maintaining laboratory accreditation while continuously striving for improvement.
Arnaldo Augusto Arbini, M.D.
Director of Hematopathology at NYU-Langone Medical Center
New York City, New York
Dr. Arbini is a distinguished hematopathologist renowned for his expertise in the field of hematopathology. Currently at the pinnacle of his career as director of hematopathology division at NYU.
Arnaldo Augusto Arbini, M.D.
Director of Hematopathology at NYU-Langone Medical Center
New York City, New York
Dr. Arbini is a distinguished hematopathologist renowned for his expertise in the field of hematopathology. Currently at the pinnacle of his career as director of hematopathology division at NYU. Dr. Aribi has trained numerous residents and fellows, including the founder, and some of the nation’s leading hematopathologists contributing significantly to the field. Dr. Arbini’s expertise is pivotal in Nanogene, especially in his diagnostic skills and review of hematology specimens for early and Minimal Residual Diseases.
Notably, Dr. Arbini holds an Associate Professorship (Clinical) in Pathology at NYU School of Medicine since 2014 and has been the Director of the Hematopathology Section at NYU Langone Medical Center since the same year. His education spans from Liceo de Cervantes, Barranquilla, Colombia, to Pontifical Xavierian University, Bogota, Colombia, and the University of Milan, Italy. His background training includes fellowships in Hematology and Hematopathology at prestigious institutions in Italy and the USA.
Dr Arbini is licensed and bord certified in Anatomic and Clinical Pathology and Hematology by The American Board of Pathology. Dr. Arbini has held numerous academic and hospital appointments across the United States, including Harvard Medical School, University of Rochester, and UT Southwestern Medical Center.
An avid cyclist, Dr. Arbini is one of New York's seasoned cyclists, having participating in multiple championships, adding a unique dimension to his accomplished professional life. Dr. Arbini's extensive academic achievements, combined with his clinical expertise and passion for cycling, make him an invaluable asset to Nanogene and the broader medical community.
Current Appointments and Leadership Positions
Academic Appointment:
- Since 2014: Associate Professor (Clinical) in Pathology at NYU School of Medicine, New York, NY
Hospital Appointment:
- Since 2014: Director of the Hematopathology Section at NYU Langone Medical Center, New York, NY
Education and Training
- 1977: Bachelor's Degree, Liceo de Cervantes, Barranquilla, Colombia
- 1983: M.D., Pontifical Xavierian University, Bogota, Colombia
- 1994: M.D., University of Milan, Milan, Italy
Internships and Residencies
- 1986-1988: Internal Medicine, St. Clara Hospital, Pontifical Xavierian University, Bogota, Colombia
- 1996-2000: Pathology & Laboratory Medicine, Yale-New Haven Hospital, Yale School of Medicine, New Haven, CT
Clinical and Research Fellowships
- 1989-1992: Hematology, A. Bianchi-Bonomi Hemophilia and Thrombosis Center, University of Milan, Italy
- 1994-1996: Hematology, Kenneth A. Bauer, MD Laboratory, Beth Israel Hospital and West Roxbury VAMC, Harvard Medical School, Boston, MA
- 2000-2001: Hematopathology, Cornell Weill Medical College, New York, NY
Licensure and Certification
- Connecticut Medical License (Inactive), New York Medical License (Active), Texas Medical License (Active)
- Certification in Anatomic and Clinical Pathology, Hematology, The American Board of Pathology
Academic Appointments
- 1994-1997: Instructor in Medicine, Harvard Medical School, Boston, MA
- 2001-2006: Assistant Professor in Pathology, University of Rochester School of Medicine and Dentistry, Rochester, NY
- 2006-2010: Associate Professor in Pathology, UT Southwestern School of Medicine, Dallas, TX
- 2011-Present: Clinical Associate Professor in Pathology, New York University School of Medicine, New York, NY
Hospital Appointments
- 2001-2006: Attending Physician, Strong Memorial Hospital, Rochester, NY
- 2006-2010: Attending Physician, UT Southwestern Medical Center, Dallas, TX
- 2007-2010: Director of Morphology Services in Hematopathology, UT Southwestern Medical Center, Dallas, TX
- 2011-Present: Active Attending, NYU Langone Medical Center/Tisch Hospital, New York, NY
- Associate Attending in Pathology, Bellevue Hospital, New York, NY
Other Professional Positions
- 1984-1985: Physician, Rural Social Service, Institute of Social Services, Tasco, Colombia.
Awards and Honors
- ASH travel awards (1993, 1994), A. Bianchi-Bonomi International Prize to Young Investigators (1995), Halina Goldstein Autopsy Pathology Award, Yale School of Medicine (1997)
Memberships in Professional Societies
- American Society of Hematology, International Society on Thrombosis and Haemostasis
Editorial Positions
- Ad-Hoc Reviewer for Thrombosis and Haemostasis, Leukemia Research, Human Pathology, Cytometry
Principal Clinical and Hospital Service Responsibilities
- Attending Hematopathologist at various renowned hospitals and medical centers, including Strong Memorial Hospital, UT Southwestern Medical Center, and NYU Langone Medical Center. Director of Morphology in Hematopathology at UT Southwestern Medical Center and Director of Hematopathology at NYU Langone Medical Center.
Book Reviews:
-
Flow Cytometry in Hematopathology: A visual approach to data analysis and interpretation. Leukemia Research2003; 27:1067-8
-
Methods in Molecular Biology: Flow Cytometry Protocols, 2nd. Edition. Leukemia Research 2005; 29:109-10.
Original reports [1-55]
-
Xue, H., et al., African American patients with Multiple Sclerosis (MS) have higher proportions of CD19+ and CD20+ B-cell lineage cells in their cerebrospinal fluid than White MS patients. Mult Scler Relat Disord, 2023. 79: p. 105047.
-
Feng, J., et al., Haplodeficiency of the 9p21 tumor suppressor locus causes myeloid disorders driven by the bone marrow microenvironment. Blood, 2023. 142(5): p. 460-476.
-
Boyle, E.M., et al., Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma. Clin Cancer Res, 2023. 29(19): p. 3901-3913.
-
Saidenberg, L., et al., Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases. Mult Scler Relat Disord, 2022. 63: p. 103830.
-
Marzio, A., et al., EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion. Cell, 2022. 185(1): p. 169-183 e19.
-
Boyle, E.M., et al., Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. Leukemia, 2022. 36(1): p. 221-224.
-
Simoneschi, D., et al., CRL4(AMBRA1) is a master regulator of D-type cyclins. Nature, 2021. 592(7856): p. 789-793.
-
Kister, I., et al., CSF plasmablasts differentiate MS from other neurologic disorders. Mult Scler Relat Disord, 2021. 48: p. 102719.
-
Duan, S., et al., Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis. Cell Rep, 2021. 37(3): p. 109870.
-
Boyle, E.M., et al., The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat Commun, 2021. 12(1): p. 293.
-
Moro, L., et al., Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis. Nat Cell Biol, 2020. 22(9): p. 1130-1142.
-
Marzio, A., et al., The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers. Mol Cell, 2019. 73(2): p. 224-237 e6.
-
Lo, U.G., et al., IFNgamma-Induced IFIT5 Promotes Epithelial-to-Mesenchymal Transition in Prostate Cancer via miRNA Processing. Cancer Res, 2019. 79(6): p. 1098-1112.
-
Ronny, F.M.H., M.A. Black, and A.A. Arbini, Intravascular large B-cell lymphoma with multi-organ failure presenting as a pancreatic mass: a case with atypical presentation and definite diagnosis postmortem. Autops Case Rep, 2017. 7(4): p. 30-36.
-
Guerra, F., et al., Mitochondrial Dysfunction: A Novel Potential Driver of Epithelial-to-Mesenchymal Transition in Cancer. Front Oncol, 2017. 7: p. 295.
-
Guerra, F., A.A. Arbini, and L. Moro, Mitochondria and cancer chemoresistance. Biochim Biophys Acta Bioenerg, 2017. 1858(8): p. 686-699.
-
Gazzola, D.M., et al., Author response: Primary marginal zone lymphoma of the CNS presenting as a diffuse leptomeningeal process. Neurology, 2017. 88(10): p. 1007-1008.
-
Moro, L., et al., [Corrigendum] Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2. Int J Oncol, 2016. 48(6): p. 2722.
-
Horton, J.D., et al., Rapid and robust reversion to essential thrombocythemia on treatment with Decitabine in a case of hydroxyurea-induced t-MDS/AML. Clin Case Rep, 2016. 4(1): p. 46-50.
-
Gazzola, D.M., et al., Primary marginal zone lymphoma of the cns presenting as a diffuse leptomeningeal process.Neurology, 2016. 87(11): p. 1180-2.
-
Storey, P. and A.A. Arbini, Bone marrow uptake of ferumoxytol: a preliminary study in healthy human subjects. J Magn Reson Imaging, 2014. 39(6): p. 1401-10.
-
Giannattasio, S., et al., Stress-related mitochondrial components and mitochondrial genome as targets of anticancer therapy. Chem Biol Drug Des, 2013. 81(1): p. 102-12.
-
Arbini, A.A., et al., Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2. Oncogenesis, 2013. 2: p. e82.
-
Schuster, K., et al., Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo. Blood Cancer J, 2011. 1(9): p. e34.
-
Arbini, A.A., et al., Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer. Am J Pathol, 2011. 178(5): p. 2367-76.
-
Tirado, C.A., et al., Acute myeloid leukemia with inv(16) with CBFB-MYH11, 3'CBFB deletion, variant t(9;22) with BCR-ABL1, and del(7)(q22q32) in a pediatric patient: case report and literature review. Cancer Genet Cytogenet, 2010. 200(1): p. 54-9.
-
Tirado, C.A., et al., Unusual presentation of myeloid sarcoma in a case of acute promyelocytic leukemia with a cryptic PML-RARA rearrangement involving multiple sites including the atrium. Cancer Genet Cytogenet, 2010. 200(1): p. 47-53.
-
Moro, L., et al., Aromatase deficiency inhibits the permeability transition in mouse liver mitochondria.Endocrinology, 2010. 151(4): p. 1643-52.
-
Moro, L., et al., Mitochondrial DNA depletion in prostate epithelial cells promotes anoikis resistance and invasion through activation of PI3K/Akt2. Cell Death Differ, 2009. 16(4): p. 571-83.
-
Deisch, J., et al., Segmental tandem triplication of the MLL gene in an intravascular large B-cell lymphoma with multisystem involvement: a comprehensive morphologic, immunophenotypic, cytogenetic, and molecular cytogenetic antemortem study. Arch Pathol Lab Med, 2009. 133(9): p. 1477-82.
-
Moro, L., et al., Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9. Cancer Sci, 2008. 99(3): p. 553-63.
-
Moro, L., et al., Mitochondrial DNA depletion reduces PARP-1 levels and promotes progression of the neoplastic phenotype in prostate carcinoma. Cell Oncol, 2008. 30(4): p. 307-22.
-
Maftoun-Banankhah, S., et al., Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes. Am J Clin Pathol, 2008. 129(2): p. 300-8.
-
Moro, L., et al., Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2. Int J Oncol, 2007. 30(1): p. 217-24.
-
Yao, Z., et al., Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem, 2006. 281(17): p. 11846-55.
-
Vargas, R.L., et al., Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience. Leuk Res, 2006. 30(5): p. 547-51.
-
Moro, L., et al., Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation. J Biol Chem, 2006. 281(31): p. 22100-22107.
-
Egbuna, O., et al., A cluster of parvovirus B19 infections in renal transplant recipients: a prospective case series and review of the literature. Am J Transplant, 2006. 6(1): p. 225-31.
-
Moro, L., et al., Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation. J Biol Chem, 2005. 280(23): p. 22482-91.
-
Lee, S.K., A.A. Arbini, and M.T. Galloway, Angioleiomyoma of the patellar tendon sheath. Case report. Am J Knee Surg, 2001. 14(3): p. 178-80.
-
Rinder, H.M., A.A. Arbini, and E.L. Snyder, Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol, 1999. 6(6): p. 437-41.
-
Hunault, M., et al., Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII. Blood, 1999. 93(4): p. 1237-44.
-
Hunault, M., et al., Mechanism underlying factor VII deficiency in Jewish populations with the Ala244Val mutation. Br J Haematol, 1999. 105(4): p. 1101-8.
-
Hunault, M., et al., The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. Arterioscler Thromb Vasc Biol, 1997. 17(11): p. 2825-9.
-
Arbini, A.A., et al., Severe factor VII deficiency due to a mutation disrupting a hepatocyte nuclear factor 4 binding site in the factor VII promoter. Blood, 1997. 89(1): p. 176-82.
-
Arbini, A.A., M. Mannucci, and K.A. Bauer, A Thr359Met mutation in factor VII of a patient with a hereditary deficiency causes defective secretion of the molecule. Blood, 1996. 87(12): p. 5085-94.
-
Eichinger, S., et al., Determinants of plasma factor VIIa levels in humans. Blood, 1995. 86(8): p. 3021-5.
-
Arbini, A.A., P.M. Mannucci, and K.A. Bauer, Low prevalence of the factor V Leiden mutation among "severe" hemophiliacs with a "milder" bleeding diathesis. Thromb Haemost, 1995. 74(5): p. 1255-8.
-
Arbini, A.A., et al., Molecular analysis of Polish patients with factor VII deficiency. Blood, 1994. 84(7): p. 2214-20.
-
Tripodi, A., et al., Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders. Br J Haematol, 1993. 84(4): p. 670-4.
-
Tripodi, A., et al., Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost, 1993. 70(2): p. 286-8.
-
Tripodi, A., et al., Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the international normalized ratio? Thromb Haemost, 1993. 70(6): p. 921-4.
-
Martinelli, I., et al., Ischemic stroke in congenital (type II C) defective antithrombin III. Int J Clin Lab Res, 1993. 23(4): p. 212-4.
-
Tripodi, A., et al., Recombinant tissue factor as substitute for conventional thromboplastin in the prothrombin time test. Thromb Haemost, 1992. 67(1): p. 42-5.
-
Chantarangkul, V., et al., Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. Thromb Res, 1992. 67(4): p. 355-65.
Soufiane El Hallani, M.D.
Molecular and Gynecologic Pathologist
University of Alberta, Canada
American Board Certified in Anatomical & Molecular Pathology
Dr. Soufiane El Hallani is a seasoned Molecular Pathologist with extensive expertise in molecular and genetic pathology. He plays a key role in Nanogene's acquisition and implementation of cutting-edge molecular platforms.
Soufiane El Hallani, M.D.
Molecular and Gynecologic Pathologist University of Alberta, Canada
American Board Certified in Anatomical & Molecular Pathology
Dr. Soufiane El Hallani is a seasoned Molecular Pathologist with extensive expertise in molecular and genetic pathology. He plays a key role in Nanogene's acquisition and implementation of cutting-edge molecular platforms. With a background in prestigious institutions worldwide, Dr. El Hallani brings a wealth of knowledge to the field. He holds a Doctorate in Ph.D. in Oncology and Cancer Biology from the University of Paris-Sud, and he completed post-doctoral research at the British Columbia Cancer Agency in the field of Digital Pathology.
Dr. El Hallani is a certified Anatomical Pathologist by the Royal College of Physicians and Surgeons of Canada and the American Board of Pathology. He is an esteemed member of several professional organizations, including the Association for Molecular Pathology and the United States and Canada Academy of Pathology. Currently, he serves as an Assistant Professor in the Department of Laboratory Medicine and Pathology at the University of Alberta and is an active member of the Women and Children's Health Research Institute.
Degrees
- 2017/07 – 2018/06 Stanford University Hospital, Palo Alto, CA, USA
Certificate, Gynecologic Pathology Fellowship
- 2016/07 – 2017/06 University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Certificate, Molecular and Genetic Pathology Fellowship
- 2011/07 – 2016/06 University of Ottawa, Ottawa, ON, Canada
Certificate, Anatomical Pathology Residency
- 2009/10 – 2011/05 British Columbia Cancer Agency, Vancouver, BC, Canada
Post-doctoral Research Fellowship in Digital Pathology
- 2007/09 – 2009/09 University of Paris - Sud, Gustave Roussy Institute, France
Doctorate, Ph.D. in Oncology and Cancer Biology
- 2006/09 – 2007/08 University of Paris - XII, Val-De-Marne, France
Master, Surgical Sciences and Oncology
- 2004/09 – 2006/08 University of Pierre and Marie Curie, Paris, France
Certificate, Human Genetics, and Molecular Biology
- 1999/09 – 2006/11 Cadi Ayyad University, Marrakech, Morocco
Doctor of Medicine
Professional certifications:
Royal College of Physicians and Surgeons of Canada, FRCPC
- Anatomical Pathology certification, 2016
American Board of Pathology
- Anatomical Pathology certification, 2016
- Molecular Genetic Pathology certification, 2017
License of Medical Council of Canada (LMCC)
Affiliations and Memberships
- 2018/11 – Present Assistant Professor, University of Alberta
- Department of Laboratory Medicine and Pathology
- 2020/02 – Present Member, Women and Children’s Health Research Institute
- 2016/06 – Present Association for Molecular Pathology
- 2011/09 – Present United States and Canada Academy of Pathology
Previous Employment
Molecular Pathologist (2018/08 – present)
Molecular Pathology Laboratory - North, Alberta Precision Labs
- Delivered routine Molecular & Genetic test interpretation to ensure the highest quality of patient care in solid tumors and hematologic malignancies using various techniques (NGS, Q-PCR, fragment sizing, MassArray, Sanger sequencing, FISH).
- Worked in a regulated laboratory environment with hands-on experience in daily QA activities and CPSM accreditation for the molecular genetic pathology laboratory.
Anatomical Pathologist (2018/08 – present)
Royal Alexandra Hospital, Alberta Precision Labs
- Practiced in a mixed surgical pathology service in a tertiary hospital setting.
- Served as a consultant in the frozen section and gross rooms.
- Member of Edmonton-zone gynecologic pathology subspecialty group, consultation and review of complex gynecologic pathology cases, and weekly gynecologic oncology tumor board presentations.
Dr. Soufiane El Hallani
Leadership
Board Certification
Scientific Director, North sector (2021/10 – Present)
Molecular Pathology Program
Alberta Precision Labs
- Restructuration, design, and implementation of strategies for the continuous development of molecular services in APL organization.
- Development of innovative molecular services from idea generation, internal and external stakeholders’ engagement, and business case writing to deliverable programs.
- Direct supervision of clinical molecular assay validations.
- Engagement with the research community at the University of Alberta to foster translational research programs in molecular pathology.
- Development, validation, and deployment of a web interface for integrated review of NGS results, variant interpretation database, and automated report generation (TALOMAR software).
- Development of bioinformatics infrastructure, bioinformatics pipelines, and database management in a clinical lab setting.
Chair, Somatic Cancer – Solid Tumors Working Group (2020/03 – Present)
Genetics and Genomics/Molecular Pathology Discipline Council
Alberta Precision Labs
- Designed and implemented a pilot province-wide integrated NGS workflow for centralized processing/decentralized reporting within Alberta Precision Labs.
- Promoted the NGS strategy in the province of Alberta by delivering an integrated financial, technical and operational plan to achieve cost-efficiency and improve the standard of care.
- Developed multiple business cases and recommendations for molecular pathology testing in Alberta by engaging multiple stakeholders including clinicians, pathologists, medical genetics, operation managers, and the finance department (homologous deficiency testing in ovarian and prostate cancers, gliomas, endometrial classification, solid tumor diagnosis and grading, diagnostic thyroid and pancreaticobiliary cytology, gene expression profiling of breast cancers, radioiodine refractory thyroid cancers, lung cancer biomarkers).
- Developed provincial guidelines for variant interpretation and reporting in molecular pathology to improve patient safety.
Molecular Subspecialty Lead for Gynecology/Neuropathology/Genitourinary programs
- Molecular Pathology division, Alberta Precision Labs (2020/03 – Present)
Health Advocacy CanMeds Champion (2012/07 – 2015/06)
Pathology and Laboratory Medicine, University of Ottawa
- Promoted the health advocacy role as per the Canada guidelines among staff in the department of pathology and laboratory medicine (The Ottawa Hospital).
- Co-organized an intradepartmental health advocacy workshop tailored to pathology services.
- Managed an international global health advocacy program to support cervical cancer screening in low-resource settings using artificial intelligence technologies to automate the Pap smear screening.
Jason Pimentel, M.D., FRCPA, DABP
Dermatopathology – Mayo Clinic
Dr. Pimentel embarked on his medical education at the University of Texas Medical Branch in Galveston, Texas before transferring to the University of New South Wales in Sydney, Australia.
Jason Pimentel, MD, FRCPA, DABP
(Dermatopathology – Mayo Clinic)
Dr. Pimentel embarked on his medical education at the University of Texas Medical Branch in Galveston, Texas before transferring to the University of New South Wales in Sydney, Australia. He successfully completed his internship and five additional years of training to become a Fellow of the Royal College of Pathologists of Australasia in Medical Microbiology. Dr. Pimentel then returned to the United States to pursue residency in Anatomical and Clinical Pathology, including two years serving as Chief Resident, at Henry Ford Hospital, in Detroit, Michigan. Subsequently, he completed a specialized fellowship in Dermatopathology at the Mayo Clinic in Rochester, Minnesota. It's worth noting that the Mayo Clinic laboratory receives numerous consultation pathology cases from the UAE and the wider region.
Since 2013, Dr. Pimentel has been actively practicing as a board-certified dermatopathologist for the Henry Ford Health System, where he has risen to the position of Chief of Pathology and Laboratory Medical Director at Henry Ford West Bloomfield Hospital. His wealth of knowledge spans both inflammatory and neoplastic skin diseases. Dr. Pimentel is renowned for his expertise and exceptional skills, which undoubtedly make him an asset to the Dermatopathology division at Nanogene. Dr. Pimentel is known for his excellent communication skills and always welcomes medical discussions and opportunities for collaboration with Nanogene providers.
EDUCATION:
- 2012-2013 Mayo Clinic, Rochester, MN, USA
Fellowship: Dermatopathology - 2008 - 2012 Henry Ford Hospital/Wayne State University, Detroit, MI, USA
Residency: Anatomic Pathology and Clinical Pathology - 2004 - 2008 Royal College of Pathologists of Australasia, Sydney, NSW, Australia
Specialty: Medical Microbiology (various institutions, see below) - 2003 - 2004 Queensland Health, The Townsville Hospital, Townsville, QLD, Australia
- 2003 - 2004 Queensland Health, The Townsville Hospital, Townsville, QLD, Australia Internship
- 2001 - 2002 University of New South Wales, Faculty of Medicine, Sydney, NSW, Australia
Medical School: Degree - MBBS - 1997 - 2000 University of Texas Medical Branch, School of Medicine, Galveston, TX, USA
Medical School: Subjects - Basic and Clinical Sciences (prior to transfer to UNSW, in good standing) - 1993 - 1997 University of Texas at Austin, School of Natural Sciences, Austin, TX, USA
Undergraduate: Degree - BA (Major: Biology; Minor: Chemistry)
SPECIALIST CERTIFICATION:
- 2013- Current American Board of Pathology: Diplomat (DABP; Dermatopathology)
- 2012- Current American Board of Pathology: Diplomat (DABP; Anatomic Pathology and Clinical Pathology)
- 2009- Current Royal College of Pathologists of Australasia: Fellow (FRCPA; Medical Microbiology)
Scott Reading, Ph.D
Molecular Pathology Scientist, level IV ARUP Laboratory
Scott Reading, Ph.D., is a seasoned Senior Scientist specializing in molecular diagnostics and laboratory research. With a strong background in Biochemistry and Molecular Biology, Scott brings extensive expertise to his role at Nanogene...
Scott Reading, Ph.D
Molecular Pathology Scientist, level IV ARUP Laboratory
Assistant Professor at the University of Utah School of Medicine.
Scott Reading, Ph.D., is a seasoned Senior Scientist specializing in molecular diagnostics and laboratory research. With a strong background in Biochemistry and Molecular Biology, Scott brings extensive expertise to his role at Nanogene.He plays a key role in designing and validating genetic, oncology, and hematology molecular assays, incorporating advanced technologies to enhance efficiency and cost-effectiveness. Scott has presented his research at prestigious conferences and published in peer-reviewed journals.
As an Adjunct Assistant Professor at the University of Utah School of Medicine, Scott mentors students, fellows, and visiting professors in molecular techniques. His involvement in collaborative grants on Myeloproliferative disorders demonstrates his commitment to advancing scientific knowledge.
During his tenure at Utah State University and Brigham Young University, Scott conducted pioneering research, including the redesign of a protein for enhanced stability and the development of an innovative viral disease detection assay for mink.
Scott Reading's extensive expertise and groundbreaking research make him an invaluable addition to our team as a Molecular Diagnostic Scientist and Laboratory Research Assistant
Academic Preparation:
- Ph.D. in Biochemistry, Utah State University, 2002
- Concentrations: Biochemistry, Molecular Biology
- Dissertation: Structure-function relationships for manganese peroxidase from Phanerochaetechrysosporium.
- Advisor: Dr. Steven D. Aust
- B.S. in Microbiology, Brigham Young University, Provo, UT, 1990
- Concentrations: Microbiology, Molecular Genetics
Professional Experience:
- Scientist IV, ARUP Laboratories, Inc., Salt Lake City, UT (2001 - Present)
- Design, development, and validation of genetic, oncology, and hematology molecular and biochemical assays
- Implementation of technological advancements for improved efficiency
- Research presentation at various professional forums and publications
- Adjunct Assistant Professor, University of Utah School of Medicine (2015 - Present)
- Mentorship of students and fellows in molecular techniques and analyses
- Contribution to collaborative grants on Myeloproliferative disorders
- Research Assistant, Utah State University, Logan, UT (1994-2001)
- Conducted independent research on a heme-peroxidase from a wood-rotting fungus
- Research Assistant, Brigham Young University, Provo, UT (1989-1994)
- Developed an immunological assay for detecting viral diseases in mink
Significant Accomplishments:
- Molecular redesign of a protein with 2 additional disulfide bonds for enhanced enzymatic stability
- Identification of the role of heme structure in enzyme redox potential and activity.
Konstantinos Linos, M.D.
Soft Tissue Pathology & Dermatopathology
Memorial Sloan Kettering Cancer Center (MSKCC) New York City, NY
Dr. Konstantinos Linos received his medical degree from Athens School of Medicine in Athens, Greece, followed by a residency in Anatomic and Clinical Pathology at Albany Medical Center in Albany, New York.
Konstantinos Linos, M.D
Soft Tissue Pathology & Dermatopathology
Memorial Sloan Kettering Cancer Center (MSKCC) New York City, NY
Dr. Konstantinos Linos received his medical degree from Athens School of Medicine in Athens, Greece, followed by a residency in Anatomic and Clinical Pathology at Albany Medical Center in Albany, New York, USA, where he served as the chief resident. He continued his training at Memorial Sloan Kettering Cancer Center in New York, completing the Oncologic Surgical Pathology Fellowship. Subsequently, he pursued a Bone & Soft Tissue Pathology Fellowship at Emory University under the mentorship of Sharon Weiss, a renowned pathologist in Soft Tissue tumors known for her significant contributions through published books and seminars across the United States. He concluded his training with a dermatopathology fellowship at Indiana University.
During his tenure at Dartmouth Hitchcock Medical Center, Dr. Linos specialized in Dermatopathology and Bone & Soft Tissue Pathology, simultaneously serving as the director of the Bone & Soft Tissue Pathology Division. He achieved the rank of Associate Professor at the Geisel School of Medicine at Dartmouth. In 2022, he joined the Pathology Department of Memorial Sloan Kettering Cancer Center in New York, where he currently practices both Dermatopathology and Bone & Soft Tissue Pathology, holding the position of Associate Professor. Dr. Linos has authored numerous articles and book chapters in his field and has been invited to deliver lectures in both Europe and the USA on multiple occasions, contributing significantly to the advancement of pathology.
EDUCATION
- MD from Athens Medical School in 2002
POSTDOCTORAL TRAINING
- Anatomic & Clinical Pathology Residency at Albany Medical Center, NY from 07/2007 to 06/2011
- Oncological Pathology Fellowship at Memorial Sloan Kettering Cancer Center, NY from 07/2011 to 06/2012
- Bone & Soft Tissue Pathology Fellowship at Emory University, GA from 07/2012 to 06/2013
- Dermatopathology Fellowship at Indiana University, IN from 07/2013 to 06/2014
Board Certification
- American Board of Pathology (Anatomic and Clinical Pathology), Certificate # 11-234, certified from 07/29/2011 with no expiration date
- American Board of Dermatopathology, Certificate # S-14-228, certified from 09/09/2014 to 12/31/2024
PROFESSIONAL POSITIONS & EMPLOYMENT
Academic Appointments
- Assistant Professor of Pathology at Geisel School of Medicine at Dartmouth from 07/2014 to 02/2021
- Associate Professor of Pathology at Geisel School of Medicine at Dartmouth from 02/2021 to 01/2022
Hospital Appointments
- Attending Physician at Dartmouth Hitchcock Medical Center from 07/2014 to 01/2022
- Associate Attending at Memorial Sloan Kettering Cancer Center from 03/2022 to present
LICENSURE
- Licensure in New Hampshire, Vermont, New York, and New Jersey with varying issue and expiration dates
HONORS, AWARDS
- Physician-in-Training Award for the Best Resident/Fellow Poster Abstract Presentation from the American Society of Dermatopathology in 2023
- Several awards from the American Society of Dermatopathology in 2015, 2016, and 2017
- Presidential citation for participation in the “Appropriate Use Criteria for Immunostains and Molecular Studies” Task Force from the American Society of Dermatopathology in 2015
- Chief Resident, Pathology at Albany Medical Center, Pathology Residency Program in 2010
- Associate Lecturer title in recognition of teaching University of Queensland Medical School students in 2006
Avi Rosenberg, M.D., Ph.D.
Kidney and Placental Pathologist
Johns Hopkins School of Medicine Baltimore, MD
Dr. Rosenberg is a physician-scientist and renal pathologist from the Johns Hopkins University School of Medicine, is poised to bring his expertise to Nanogene Laboratory. In his new role, Dr. Rosenberg will provide advanced consultation services, specializing in medical and renal transplant biopsies.
Avi Z. Rosenberg, M.D., Ph.D.
Kidney and Placental Pathologist
Johns Hopkins University School of Medicine, Baltimore, Maryland
Dr. Avi Rosenberg, a distinguished physician-scientist and renal pathologist from the Johns Hopkins University School of Medicine, is poised to bring his expertise to Nanogene Laboratory. In his new role, Dr. Rosenberg will provide advanced consultation services, specializing in medical and renal transplant biopsies. His deep-seated interest and extensive experience in renal pathology make him an invaluable addition to the team.
Dr. Rosenberg's academic journey includes notable collaborations and innovations. During his doctorate, he worked with Dr. Michael Emmert-Buck, co-developing an enhanced microdissection technique, expression microdissection (as documented in PLoS One. 2016), aimed at improving the precision and efficiency of cell-specific and subcellular microdissection for bioanalyte analysis.
At the NIH, Dr. Rosenberg cultivated a profound interest in primary kidney diseases. This led him to work in Dr. Jeffrey Kopp's lab and collaborate with Dr. Moshe Levi, gaining expertise in various models of kidney diseases such as focal and segmental glomerulosclerosis, diabetes, obesity-related glomerulopathy, and microangiopathic injuries. His approach to complex renal issues is comprehensive, utilizing a wide range of molecular, cellular, and analytical tools.
In addition to his research, Dr. Rosenberg leads a research group comprising a postdoctoral fellow and a research specialist. He is passionate about teaching, having instructed medical students and residents, and is committed to inspiring future physician-scientists to delve deeper into disease mechanisms.
Dr. Rosenberg completed his M.D. and Ph.D. at Stony Brook University, where his research at the Cold Spring Harbor Laboratory under Dr. Senthil Muthuswamy focused on polarity regulators in breast development and neoplasia.
Education
Degrees
• M.D., Medicine, SUNY at Stony Brook School of Medicine, 2011
Residencies
• Anatomic Pathology, National Institutes of Health, 2014 Fellowships
• Pathology, Children's National Hospital, 2016
• Johns Hopkins University School of Medicine, 2015
Board Certifications
• American Board of Pathology (Pathology), 2016
Activities & Honors
Honors
• Betta Kappa Society
• BA/BS Magna cum laude, Brooklyn College Honors Academy – Scholars Program, 1997-2001
• Medical Scientist Training Program, Stony Brook University, 2001-2011
• Co-chief Resident, Anatomic Pathology Training Program, Laboratory of Pathology, NIH, 2013-2014
• Outstanding Poster Award, Renal Pathology Society, USCAP, 2015
• Gary S. Hill Award, 2017
Memberships
• United States and Canadian Academy of Pathology
• Renal Pathology Society
• Society of Pediatric Pathology
• Association for Molecular Pathology
• American Society of Nephrology
• American Society of Mass Spectroscopy
• Professional Activities
• Finance Committee, Renal Pathology Society
• Perinatal Pathology Committee, Society of Pediatric Pathology
YOUR PATHWAY TO EARLY DIAGNOSIS
Every day, we help healthcare providers treat patients through early detection testing. From specialty diagnostics to cutting-edge science in oncology, chronic diseases, and more, we never stop delivering innovative resources.